BIOGEN INC. (BIIB) — SEC Filings

Latest SEC filings for BIOGEN INC. (BIIB), explained in plain English.

Sentiment Overview: 30 neutral, 2 mixed

Recent Filings (32)

• Biogen Inc. Files 8-K for Financial Results — 8-K · 2026-04-06T06:31:37-04:00 [neutral] Risk: low
  Biogen Inc. filed an 8-K report on April 6, 2026, to disclose its results of operations and financial condition. The filing includes various XBRL documents deta
• Biogen's Q3 Net Income Jumps 20% on Revenue Growth — 10-Q · 2025-10-30T00:00:00.000Z [mixed] Risk: medium
  Biogen Inc. reported a mixed financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased to $2,53
• Biogen Inc. Files 8-K on Financials — 8-K · 2025-10-14T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on October 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhib
• Biogen's Q2 Revenue Dips Amid LEQEMBI Ramp-Up — 10-Q · 2025-07-31T00:00:00.000Z [mixed] Risk: medium
  Biogen Inc. reported total revenues of $2.70 billion for the second quarter of 2025, a decrease from $2.85 billion in the second quarter of 2024. Product revenu
• Biogen Inc. Files 8-K on Financials — 8-K · 2025-07-07T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on July 7, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits,
• Biogen Inc. Files 8-K on Shareholder Votes and Financials — 8-K · 2025-06-23T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on June 23, 2025, reporting on events that occurred on June 17, 2025. The filing primarily concerns the submission of matters to a vote
• Biogen Inc. Files Proxy Statement Addendum — DEFA14A · 2025-06-02T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed a Definitive Additional Materials (DEFA14A) document on June 2, 2025. This filing pertains to the company's proxy statement, indicating it's p
• Biogen Inc. Files 8-K: Other Events & Exhibits — 8-K · 2025-05-12T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on May 12, 2025, reporting an event that occurred on May 6, 2025. The filing pertains to 'Other Events' and includes 'Financial Stateme
• Biogen Inc. Q1 2025 10-Q Filed — 10-Q · 2025-05-01T00:00:00.000Z [neutral] Risk: medium
  Biogen Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenues from its anti-CD20 therapeutic programs and LEQEMBI collaboration
• Biogen Inc. Files 2025 DEF 14A on Executive Compensation — DEF 14A · 2025-04-28T00:00:00.000Z [neutral] Risk: medium
  Biogen Inc. filed its DEF 14A on April 28, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024.
• Biogen Inc. Files 8-K on Financials — 8-K · 2025-02-12T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on February 12, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The
• Biogen Inc. Announces Board and Executive Changes — 8-K · 2025-01-15T00:00:00.000Z [neutral] Risk: medium
  Biogen Inc. announced on January 13, 2025, changes in its board of directors and executive compensation. Specifically, Dr. Al Sandage, Jr. resigned from the Boa
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-07T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-04T00:00:00.000Z [neutral]
• Biogen Inc. Files 8-K: Director & Officer Changes — 8-K · 2024-10-30T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on October 30, 2024, reporting changes in its board of directors and certain officers, along with updates to compensatory arrangements.
• Biogen Inc. Files Q3 2024 10-Q Report — 10-Q · 2024-10-30T00:00:00.000Z [neutral] Risk: medium
  Biogen Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter and
• SC 13G Filing — SC 13G · 2024-10-16T00:00:00.000Z [neutral]
• Biogen Inc. Announces Executive and Board Changes — 8-K · 2024-09-12T00:00:00.000Z [neutral] Risk: medium
  Biogen Inc. announced on September 11, 2024, changes in its executive team and board of directors. The filing details the departure of certain officers and dire
• SC 13G/A Filing — SC 13G/A · 2024-08-16T00:00:00.000Z [neutral]
• Biogen Inc. Files 8-K on Material Agreements and Obligations — 8-K · 2024-08-14T00:00:00.000Z [neutral] Risk: medium
  Biogen Inc. filed an 8-K on August 14, 2024, reporting on events that occurred on August 12, 2024. The filing indicates the entry into and termination of materi
• SC 13G/A Filing — SC 13G/A · 2024-08-07T00:00:00.000Z [neutral]
• Biogen Inc. Files 8-K on Financials — 8-K · 2024-08-01T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibit
• Biogen Inc. Files 8-K: Fiscal Year Change and Shareholder Matters — 8-K · 2024-06-25T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on June 25, 2024, reporting events that occurred on June 20, 2024. The filing indicates a change in the company's fiscal year end to De
• Biogen Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · 2024-04-26T00:00:00.000Z [neutral] Risk: low
  BIOGEN INC. (BIIB) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Biogen Inc. filed a Definitive Proxy Statement (DEF 14A) on April 26, 2024.
• Biogen Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-04-24T00:00:00.000Z [neutral] Risk: low
  BIOGEN INC. (BIIB) filed a Quarterly Report (10-Q) with the SEC on April 24, 2024. Biogen Inc. reported revenues of $145,596,895 for the quarter ending March 31
• Biogen Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-14T00:00:00.000Z [neutral] Risk: medium
  BIOGEN INC. (BIIB) filed a Annual Report (10-K) with the SEC on February 14, 2024. Biogen Inc. filed its 10-K report for the fiscal year ending December 31, 202
• Biogen Files 8-K on Financial Results, Operations — 8-K · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an 8-K on February 13, 2024, to report its results of operations and financial condition. This filing, under the Securities Exchange Act of 19
• Vanguard Boosts Biogen Stake to 12.4% as of Dec 29, 2023 — SC 13G/A · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  The Vanguard Group, a major investment firm, filed an amended Schedule 13G/A on February 12, 2024, disclosing its ownership in Biogen Inc. common stock as of De
• Biogen Amends Denali Therapeutics Stake Filing — SC 13G/A · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  Biogen Inc. filed an amended SC 13G/A on February 12, 2024, indicating a change in its beneficial ownership of Denali Therapeutics Inc. common stock as of Decem
• PRIMECAP Amends Biogen Stake, Signals Continued Passive Holding — SC 13G/A · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  PRIMECAP Management Company, an investment firm based in Pasadena, CA, filed an amended Schedule 13G/A on February 12, 2024, indicating their ownership of Bioge
• BlackRock Amends Biogen Stake, Signals Ownership Change — SC 13G/A · 2024-01-24T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, disclosing its ownership of Biogen Inc. common stock as of December 31, 2023. This amendment, numb